William H. Herman, MD, MPH; Thomas J. Hoerger, PhD; Michael Brandle, MD, MS; Katherine Hicks, MS; Stephen Sorensen, PhD; Ping Zhang, PhD; Richard F. Hamman, MD, DrPH; Ronald T. Ackermann, MD, MPH; Michael M. Engelgau, MD, MS; Robert E. Ratner, MD; Diabetes Prevention Program Research Group*
Grant Support: By the Diabetes Prevention Program, National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, Office of Research on Minority Health, National Institute of Child Health and Human Development, and National Institute on Aging; Centers for Disease Control and Prevention; Indian Health Service; General Clinical Research Program; National Center for Research Resources; American Diabetes Association; Bristol-Myers Squibb; and Parke-Davis.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: The Diabetes Prevention Program Coordinating Center, George Washington University Biostatistics Center, 6100 Executive Boulevard, Suite 750, Rockville, MD 20852; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Herman: University of Michigan Health System, 1500 East Medical Center Drive, 3920 Taubman Center, Box 0354, Ann Arbor, MI 48109-0354.
Dr. Hoerger and Ms. Hicks: RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27599-2194.
Dr. Brandle: Division of Endocrinology and Diabetes, Department of Internal Medicine, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
Dr. Sorensen: Division of Diabetes Translation, MS K-10, 4770 Buford Highway NE, Atlanta, GA 30341-3724.
Drs. Zhang and Engelgau: Division of Diabetes Translation, MS K-10, 2858 Woodcock Boulevard, Atlanta, GA 30341.
Dr. Hamman: Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Box B119, Denver, CO 80262.
Dr. Ackermann: Indiana University School of Medicine, 250 University Boulevard, Suite 122, Indianapolis, IN 46202.
Dr. Ratner: Medstar Research Institute, 6495 New Hampshire Avenue, Suite 201, Hyattsville, MD 20783.
Author Contributions: Conception and design: W.H. Herman, T.J. Hoerger, K. Hicks, S. Sorensen, P. Zhang, R.F. Hamman, R.T. Ackermann, M.M. Engelgau, R.E. Ratner.
Analysis and interpretation of the data: W.H. Herman, T.J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R.F. Hamman, R.T. Ackermann, M.M. Engelgau, R.E. Ratner.
Drafting of the article: W.H. Herman, T.J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R.F. Hamman, R.T. Ackermann, M.M. Engelgau.
Critical revision of the article for important intellectual content: W.H. Herman, T.J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R.F. Hamman, R.T. Ackermann, M.M. Engelgau, R.E. Ratner.
Final approval of the article: W.H. Herman, T.J. Hoerger, K. Hicks, S. Sorensen, P. Zhang, R.T. Ackermann, M.M. Engelgau, R.E. Ratner.
Provision of study materials or patients: P. Zhang.
Statistical expertise: W.H. Herman, T.J. Hoerger, K. Hicks, S. Sorensen, P. Zhang.
Obtaining of funding: W.H. Herman, T.J. Hoerger, K. Hicks, M.M. Engelgau. Administrative, technical, or logistic support: W.H. Herman, S. Sorensen, R.F. Hamman, M.M. Engelgau.
Collection and assembly of data: W.H. Herman, P. Zhang.
Herman W., Hoerger T., Brandle M., Hicks K., Sorensen S., Zhang P., Hamman R., Ackermann R., Engelgau M., Ratner R., ; The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Ann Intern Med. 2005;142:323-332. doi: 10.7326/0003-4819-142-5-200503010-00007
Download citation file:
Published: Ann Intern Med. 2005;142(5):323-332.
The Diabetes Prevention Program (DPP) showed that lifestyle changes or metformin effectively decreased the development of type 2 diabetes in adults with impaired glucose tolerance. The economics of these interventions is important to policymakers.
This cost-effectiveness model estimates that the DPP life-style intervention would cost society about $8800 and metformin would cost about $29 900 per quality-adjusted life-year saved. While lifestyle intervention had a favorable cost-effectiveness profile at any adult age, metformin was not cost-effective after age 65 years.
The cost-effectiveness of lifestyle intervention to prevent type 2 diabetes in high-risk individuals is within the range that American society typically finds acceptable for health care interventions.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Diabetes, Coronary Risk Factors, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only